Protagenic Therapeutics, Inc., a New York-based biopharmaceutical company, announced its focus on the discovery and development of therapeutics aimed at treating neuropsychiatric and mood disorders related to stress. With its lead compound, PT00114, the company has produced a synthetic version of teneurin carboxy-terminal associated peptide, a brain signaling peptide that can curb overactive stress responses. Protagenic Therapeutics, Inc. is dedicated to leveraging scientific research to improve the lives of those affected by stress-related disorders.